The TGF-β Family in Glioblastoma.
BMP
TGF-β
glioblastoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Jan 2024
15 Jan 2024
Historique:
received:
14
11
2023
revised:
03
01
2024
accepted:
09
01
2024
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Members of the transforming growth factor β (TGF-β) family have been implicated in the biology of several cancers. In this review, we focus on the role of TGFβ and bone morphogenetic protein (BMP) signaling in glioblastoma. Glioblastoma (GBM) is the most common malignant brain tumor in adults; it presents at a median age of 64 years, but can occur at any age, including childhood. Unfortunately, there is no cure, and even patients undergoing current treatments (surgical resection, radiotherapy, and chemotherapy) have a median survival of 15 months. There is a great need to identify new therapeutic targets to improve the treatment of GBM patients. TGF-βs signaling promotes tumorigenesis in glioblastoma, while BMPs suppress tumorigenic potential by inducing tumor cell differentiation. In this review, we discuss the actions of TGF-βs and BMPs on cancer cells as well as in the tumor microenvironment, and their use in potential therapeutic intervention.
Identifiants
pubmed: 38256140
pii: ijms25021067
doi: 10.3390/ijms25021067
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Magnus Bergvalls Stiftelse
ID : 2021-0424
Organisme : Magnus Bergvalls Stiftelse
ID : 2022-211
Organisme : Lars Hierta Memorial Foundation
ID : FO2022-0173
Organisme : O. E. och Edla Johanssons Vetenskapliga Stiftelse
ID : 2022
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.